Novartis accounted for about 28.9 percent of the $8 billion in total.
The German company expects to surpass 1 million SMILE procedures worldwide in 2017.
The segment has expanded quickly, despite new hurdles experienced by the early manufacturers.
The deal is expected to close by the end of the year.
A pre-approval inspection of the firm’s Tampa, Florida, facility tripped up the glaucoma drug candidate for a second time.
The value added tax adds 12 percent to the retail cost of lenses; it went into effect July 1.
Disruption of tear film homeostasis is now considered the unifying element for the disease.
The segment is expected to grow 4.2 percent over the next five years.
The technology had approval for myopia and mixed astigmatism.
The company said it would preserve its cash to pursue other opportunities.
The company is redirecting its focus to developing therapies for orphan ophthalmic diseases.
The Massachusetts company is developing drug candidates for post-surgical inflammation and dry eye.
Two US senators back a new FTC rule that would increase disclosures to patients during visit.
You are not currently logged in.
©2017 Market Scope
Lost your Password